Please provide your email address to receive an email when new articles are posted on . One-fifth of patients who received ocular steroid injections were later diagnosed with glaucoma or ocular ...

Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...

– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...

SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...

Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.

CHICAGO — Topical antibiotic prophylaxis is completely unnecessary in association with intravitreal injections, according to findings from more than 15,000 injections by a single surgeon who presented ...

PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma.